文献速递泌尿男性生殖肿瘤

一线他拉唑帕利联合恩扎卢胺对比安慰剂联合恩扎卢胺治疗同源重组修复基因改变的转移性去势抵抗性前列腺癌:随机双盲安慰剂对照3期TALAPRO-2试验的患者报告结局

First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial.
PubMed 文献 · Lancet Oncol · 2025-01-01

TALAPRO-2试验纳入399例HRR缺陷型mCRPC患者,随机接受他拉唑帕利+恩扎卢胺或安慰剂+恩扎卢胺。他拉唑帕利组GHS/QoL和尿路症状至明确恶化时间均显著延长,疼痛恶化时间组间差异未达统计学显著。

要点

  • 他拉唑帕利组GHS/QoL至明确恶化中位时间27.1个月,安慰剂组19.3个月,HR 0.69。
  • 他拉唑帕利组尿路症状至明确恶化中位时间不可估计,安慰剂组30.2个月,HR 0.56。
  • 疼痛症状至恶化中位时间两组均不可估计,HR 0.58,p=0.051。

核心结论

  • 在HRR缺陷型mCRPC患者中,他拉唑帕利联合恩扎卢胺对比安慰剂联合恩扎卢胺可延迟GHS/QoL、尿路症状及其他功能和症状量表的明确恶化。

研究设计与样本

  • TALAPRO-2为随机、双盲、安慰剂对照3期试验,在26个国家223家医院、癌症中心和医疗中心开展。
  • 纳入18岁及以上(日本≥20岁)男性,正在接受雄激素剥夺治疗,无症状或轻度症状mCRPC,ECOG体能状态0或1,未接受过延长生命的全身治疗。
  • HRR基因改变患者按1:1随机分配至口服他拉唑帕利0.5 mg每日一次或安慰剂,联合口服恩扎卢胺160 mg每日一次。
  • 患者报告结局人群包括意向治疗人群中具有基线评估和至少一次基线后评估的患者,他拉唑帕利组197例,安慰剂组197例。

主要发现

  • 他拉唑帕利组中位随访22.2个月(IQR 13.8-27.7),安慰剂组20.2个月(IQR 13.5-26.6)。
  • GHS/QoL至明确恶化中位时间他拉唑帕利组27.1个月(95%CI 21.2-不可估计),安慰剂组19.3个月(95%CI 16.6-23.0),HR 0.69(95%CI 0.49-0.97),双侧p=0.032。
  • 尿路症状至明确恶化中位时间他拉唑帕利组不可估计(95%CI 32.2-不可估计),安慰剂组30.2个月(95%CI 24.6-不可估计),HR 0.56(95%CI 0.34-0.93),双侧p=0.022。
  • 疼痛症状至恶化中位时间两组均不可估计,HR 0.58(95%CI 0.33-1.01),双侧p=0.051。
  • 过去24小时最严重疼痛(BPI-SF第3问)和一般健康状况(EQ-5D-5L)自基线变化利于他拉唑帕利组,但差异无临床意义。

临床怎么用

  • 原文结论指出,GHS/QoL、尿路症状及其他功能和症状量表的明确恶化延迟可为HRR缺陷型mCRPC患者的临床决策提供参考。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the phase 3 TALAPRO-2 trial, talazoparib plus enzalutamide significantly improved radiographic progression-free survival compared with placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer harbouring alterations in genes involved in homologous recombination repair (HRR). We aimed to assess patient-reported outcomes in patients with HRR-deficient metastatic castration-resistant prostate cancer in TALAPRO-2. METHODS: TALAPRO-2 is a randomised, double-blind, placebo-controlled, phase 3 trial conducted at 223 hospitals, cancer centres, and medical centres in 26 countries worldwide. Eligible participants were male patients aged 18 years or older (≥20 years in Japan) who were receiving ongoing androgen deprivation therapy, had asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer, an Eastern Cooperative Oncology Group performance status of 0 or 1, and had not received previous life-prolonging systemic therapy for castration-resistant prostate cancer or metastatic castration-resistant prostate cancer. Patients with HRR gene alterations were randomly assigned (1:1) using a centralised interactive web response system and a permuted block size of 4 to oral talazoparib 0·5 mg once daily or placebo, plus oral enzalutamide 160 mg once daily, stratified by previous second-generation androgen receptor pathway inhibitor (abiraterone or orteronel) or docetaxel (yes vs no) in the castration-sensitive setting. The sponsor, patients, and investigators were masked to allocation of talazoparib or placebo; enzalutamide was open-label. The primary endpoint was radiographic progression-free survival by blinded independent central review and has been reported previously. Patient-reported outcomes were assessed as secondary outcomes in the patient-reported outcomes population, which comprised patients from the intention-to-treat population with a baseline patient-reported outcome assessment and at least one post-baseline patient-reported outcome assessment. Patient-reported outcomes included time to definitive deterioration in global health status/quality of life (GHS/QoL) per European Organisation for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ-C30) and prostate cancer-specific urinary symptoms per EORTC Quality of Life Questionnaire-Prostate (QLQ-PR25), and time to deterioration in pain symptoms per Brief Pain Inventory-Short Form (BPI-SF). Mean change from baseline in GHS/QoL, overall cancer and prostate cancer-specific functioning and symptoms (per EORTC QLQ-C30 and QLQ-PR25), in pain symptoms per BPI-SF, and in general health status per EQ-5D-5L were also patient-reported secondary outcomes. This study is registered with ClinicalTrials.gov, NCT03395197, and is ongoing. FINDINGS: Between Dec 18, 2018, and Jan 20, 2022, 399 patients with HRR-deficient metastatic castration-resistant prostate cancer were enrolled and randomly assigned, of whom 197 assigned to talazoparib plus enzalutamide and 197 assigned to placebo plus enzalutamide were included in the patient-reported outcome population. Median follow-up was 22·2 months (IQR 13·8-27·7) in the talazoparib plus enzalutamide group and 20·2 months (13·5-26·6) for the placebo plus enzalutamide group. Median time to definitive deterioration of GHS/QoL was longer in the talazoparib plus enzalutamide group (27·1 months [95% CI 21·2-non-estimable]) than in the placebo plus enzalutamide group (19·3 months [16·6-23·0]; hazard ratio [HR] 0·69 [95% CI 0·49-0·97]; two-sided p=0·032). Median time to definitive deterioration in urinary symptoms was also longer in the talazoparib plus enzalutamide group (non-estimable [95% CI 32·2-non-estimable]) than in the placebo plus enzalutamide group (30·2 months [24·6-non-estimable; HR 0·56 [0·34-0·93]; two-sided p=0·022). Median time to deterioration in pain symptoms was non-estimable for both treatment groups (HR 0·58 [0·33-1·01]; two-sided p=0·051). Changes from baseline in worst pain in the past 24 h (BPI-SF, question three) and in general health status (EQ-5D-5L) also favoured talazoparib plus enzalutamide versus placebo plus enzalutamide, although the differences were not clinically meaningful. Between-group differences in mean changes from baseline in GHS/QoL, functioning, and symptoms per EORTC QLQ-C30 did not reach the clinically meaningful threshold of 10 or more points, although physical, emotional, and cognitive functioning and pain favoured talazoparib plus enzalutamide. Similarly, differences in mean changes from baseline for urinary and bowel symptoms per EORTC QLQ-PR25 favoured talazoparib plus enzalutamide, but were not clinically meaningful. INTERPRETATION: The demonstrated delays in definitive deterioration in GHS/QoL, urinary symptoms, and other functioning and symptom scales with talazoparib plus enzalutamide compared with placebo plus enzalutamide in patients with HRR-deficient metastatic castration-resistant prostate cancer provide insight that might inform clinical decisions for these patients. FUNDING: Pfizer.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Fay AP, Fizazi K, Matsubara N, et al. First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial. Lancet Oncol. 2025. PMID: 40179907. doi:10.1016/S1470-2045(25)00031-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。